普伐他汀预防高危孕妇子痫前期的作用:一项结合试验序贯分析的Meta分析
本Meta分析纳入3项随机对照试验共213例高危孕妇,比较普伐他汀与安慰剂或无治疗对子痫前期的预防效果。结果显示普伐他汀对子痫前期发生率无显著影响(RR 0.62,95%CI 0.33-1.14,P=.12)。作者认为现有研究仅为小样本初步研究,需设计良好且把握度充分的临床试验。
要点
- 普伐他汀未显著降低高危孕妇子痫前期发生率(RR 0.62,95%CI 0.33-1.14,P=.12)。
- 纳入3项随机对照试验共213例,其中106例(49.8%)分配至普伐他汀组。
- 作者指出这些仅为小样本初步研究,需设计良好且把握度充分的临床试验。
核心结论
- 本研究未能证明普伐他汀对高危孕妇预防子痫前期有益。
- 作者认为这些发现仅来自小样本初步研究,需设计良好且把握度充分的临床试验。
研究设计与样本
- 系统综述与Meta分析,纳入比较普伐他汀(任何剂量)与安慰剂或无治疗的随机对照试验。
- 纳入对象为子痫前期高危且孕周不超过20周的孕妇。
- 检索PubMed、Embase、Cochrane Central和Web of Science,从建库至2023年8月,无语言或过滤器限制。
- 纳入3项随机对照试验共213例患者,其中106例(49.8%)分配至普伐他汀组。
- 使用RStudio 4.2.2版随机效应模型计算预设结局的合并风险比,采用Cochrane偏倚风险评估工具第2版进行质量评价,并进行试验序贯分析。
主要发现
- 普伐他汀对子痫前期发生率无显著影响(风险比0.62,95%CI 0.33-1.14,P=.12)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 作者指出这些发现仅来自小样本初步研究,需设计良好且把握度充分的临床试验。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: We aimed to perform a systematic review and meta-analysis of randomized controlled trials to evaluate the prophylactic use of pravastatin in pregnant women with high-risk of preeclampsia. DATA SOURCES: PubMed, Embase, Cochrane Central, and Web of Science were searched from inception to August 2023 with no language or filters restriction. The references from included studies, previous systematic reviews, and meta-analyses were manually searched for any additional studies. STUDY ELIGIBILITY CRITERIA: Randomized controlled trials comparing pravastatin in any dose with placebo or no treatment in pregnant women with high risk for preeclampsia and up to 20 weeks of gestation were included in this meta-analysis. METHODS: We used RStudio version 4.2.2 with random effects models to compute pooled risk ratios for prespecified outcomes data. The quality assessment was conducted using version 2 of the Cochrane Risk of Bias Assessment Tool. We also performed a trial sequential analysis to evaluate the reliability of our findings. RESULTS: We included 3 randomized controlled trials comprising 213 patients, of whom 106 (49.8%) were allocated to the pravastatin group. There was no significant effect of pravastatin on the incidence of preeclampsia (risk ratio, 0.62; 95% confidence interval, 0.33-1.14; P=.12). CONCLUSION: Our study was unable to demonstrate the benefit of pravastatin for preventing preeclampsia in high-risk pregnant women. Nevertheless, these findings comprised only preliminary studies with a small number of subjects, highlighting the need of well-designed, and adequately powered clinical trials.
引用
- Provinciatto H, Barbalho ME, Almeida J, et al. The role of pravastatin in preventing preeclampsia in high-risk pregnant women: a meta-analysis with trial sequential analysis. Am J Obstet Gynecol MFM. 2023. PMID: 38109997. doi:10.1016/j.ajogmf.2023.101260
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。